|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Nodality
| Nodality 170 Harbor Way, Suite 200 South San Francisco, CA 94080 | |
| | Phone: | (650) 827-8000 | Fax: | (650) 827-8001 | Year Established: | 2003 | Main Contact: | Kathleen LaPorte, CBO | | Other Contacts: | Barbara Mittleman, MD, VP, Clinical and Head, Immunology Laura Brege, President & CEO David Spellmeyer, CTO Rachael Hawtin, PhD, VP, Research Santosh Putta, PhD, VP, Computational Sciences Mary Sigourney, VP, Quality Systems
| | Company Description | Nodality is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to bridge gaps left by traditional R&D approaches. Nodality’s proprietary functional biology platform, Single Cell Network Profiling (SCNP), provides unprecedented insights into diseases and partners’ product candidates and is applicable through the full discovery and development process, including disease profiling, drug profiling, clinical development, and life cycle management. Nodality’s teams have expertise in achieving solutions across a very broad therapeutic landscape, with a focus on immunology and oncology, including immuno-oncology. SCNP enables smarter spending decisions and is applicable across a very broad therapeutic landscape and throughout the full discovery and development process. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the discovery and development of new therapeutic compounds. | |
|
|
|
|
|